What is the recommended dosage of Kayexalate (sodium polystyrene sulfonate) for hyperkalemia?

Kayexalate (Sodium Polystyrene Sulfonate) Dosing for Hyperkalemia

For non-emergent hyperkalemia, administer Kayexalate orally at 15-60 g daily (typically 15 g one to four times daily) or rectally at 30-50 g every 6 hours, with the understanding that this agent should NOT be used for life-threatening hyperkalemia due to its delayed onset of action. 1

Critical Limitation: Not for Emergency Use

• Kayexalate has a delayed and variable onset of action (several hours to days), making it unsuitable for emergency treatment of severe or life-threatening hyperkalemia 1, 2
• For acute severe hyperkalemia, use rapid-acting treatments first: calcium, insulin/glucose, or nebulized albuterol 3, 2

FDA-Approved Dosing Regimens

Oral Administration

• Standard dose range: 15-60 g daily, administered as 15 g (four level teaspoons) one to four times daily 1
• Suspend each dose in 3-4 mL of liquid per gram of resin (water or syrup) 1
• Administer with patient in upright position 1
• Separation from other medications: Give at least 3 hours before or after other oral medications; patients with gastroparesis require 6-hour separation 1

Rectal Administration

• Dose: 30-50 g every 6 hours 1
• Administer as warm (body temperature) emulsion in 100 mL aqueous vehicle, flush with 50-100 mL fluid 1
• Retain as long as possible, then follow with cleansing enema using non-sodium containing solution 1
• Contraindication: Avoid rectal administration in neutropenic patients 2

Dose-Response Evidence

• 15 g dose: Reduces potassium by approximately 0.39-0.82 mEq/L 4, 5
• 30 g dose: Reduces potassium by approximately 0.69-0.95 mEq/L 4, 5
• 60 g dose: Reduces potassium by approximately 0.91-1.40 mEq/L 4, 5
• Higher doses produce greater potassium reduction, with a dose-response relationship demonstrated across studies 4, 5
• Time to effect is typically 14-16 hours post-administration 6

Serious Safety Warnings

Gastrointestinal Risks

• Fatal intestinal necrosis, ischemic colitis, perforation, and bleeding have been reported, with mortality rates up to 33% in some series 2, 1
• Never use concomitantly with sorbitol due to increased risk of colonic necrosis 7, 2, 1
• Avoid in patients with: obstructive bowel disease, reduced gut motility, history of bowel surgery, constipation, inflammatory bowel disease, ischemic colitis, or bowel obstruction 1
• Discontinue immediately if constipation develops 1

Electrolyte Disturbances

• Monitor serum potassium, calcium, and magnesium regularly during therapy 2, 1
• Kayexalate is not selective for potassium and binds other cations (calcium, magnesium), causing hypocalcemia and hypomagnesemia 3, 2, 1
• Each 15 g dose contains 1500 mg (65 mEq) of sodium—use caution in heart failure, severe hypertension, or marked edema 7, 2

Clinical Context and Guideline Recommendations

• The European Society of Cardiology recommends initiating potassium-lowering agents when levels are confirmed >5.0 mEq/L in patients on RAAS inhibitor therapy 7
• However, chronic use of Kayexalate should be avoided due to severe gastrointestinal risks 7
• Kayexalate has never undergone rigorous placebo-controlled testing to prove efficacy and safety 7

Preferred Alternative Agents

• For chronic hyperkalemia management, newer agents (patiromer or sodium zirconium cyclosilicate) are strongly preferred over Kayexalate due to: 7, 2
  • Faster onset of action (1-7 hours vs. hours to days)
  • No reported cases of fatal gastrointestinal injury
  • More predictable potassium reduction
  • Ability to maintain RAAS inhibitor therapy

Monitoring Requirements

• Verify elevated potassium with second sample to rule out pseudohyperkalemia from hemolysis 2
• Monitor ECG and cardiac rhythm closely, especially if QRS widening present 2
• Check serum potassium, calcium, and magnesium levels regularly during therapy 2, 1

Common Pitfalls to Avoid

• Do not use for potassium >6.5 mEq/L or life-threatening hyperkalemia—employ emergency measures instead 2, 1
• Never combine with sorbitol due to dramatically increased risk of bowel necrosis 7, 2, 1
• Do not heat the suspension as this alters resin exchange properties 1
• Prepare suspension fresh and use within 24 hours 1
• Remember the significant sodium load (1500 mg per 15 g dose) when treating patients with volume-sensitive conditions 2